Views
4 years ago

Articles Efficacy and safety of ustekinumab, a human ... - Huidarts.com

Articles Efficacy and safety of ustekinumab, a human ... - Huidarts.com

Articles Efficacy and safety of ustekinumab, a human ... -

Articles Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon, for the PHOENIX 1 study investigators* Summary Background Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody directed against these cytokines, for the treatment of psoriasis. Methods In this phase III, parallel, double-blind, placebo-controlled study, 766 patients with moderate-to-severe psoriasis were randomly assigned to receive ustekinumab 45 mg (n=255) or 90 mg (n=256) at weeks 0 and 4 and then every 12 weeks; or placebo (n=255) at weeks 0 and 4, with subsequent crossover to ustekinumab at week 12. Patients who were initially randomised to receive ustekinumab at week 0 who achieved long-term response (at least 75% improvement in psoriasis area and severity index [PASI 75] at weeks 28 and 40) were re-randomised at week 40 to maintenance ustekinumab or withdrawal from treatment until loss of response. Both randomisations were done with a minimisation method via a centralised interactive voice response system. The primary endpoint was the proportion of patients achieving PASI 75 at week 12. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00267969. Findings All randomised patients were included in the efficacy analysis. 171 (67·1%) patients receiving ustekinumab 45 mg, 170 (66·4%) receiving ustekinumab 90 mg, and eight (3·1%) receiving placebo achieved PASI 75 at week 12 (difference in response rate vs placebo 63·9%, 95% CI 57·8–70·1, p

Safety and Efficacy of Novel Combination Safety and Efficacy of ...
Efficacy and Safety of Prescription Omega-3-Acid - Clinical Trial ...
Measuring the Efficacy of Humane Education - The Latham ...
Safety and Efficacy Considerations in Endodontic ... - IneedCE.com
STUdY Of ThE EffICACY ANd SAfETY Of fLORfENICOL PREMIx ...
Long Term Efficacy and Safety of Osteoporosis Therapies - Osteos
Phase 3b UPFRONT Study: Safety and Efficacy of Weekly ...
quality, safety and efficacy of drugs - World Health Organization
The Clinical Utility Index, a Method for Balancing Efficacy and Safety ...
Efficacy and safety of viscum fraxini-2 in advanced hepatocellular
Efficacy and safety of Butterbur leaves extract Ze 339 in ... - CHUV
THE SAFETY OF PYROTECHNIC ARTICLES
Sikh articles of faith.indd - Equality and Human Rights Commission
Research Article Safety and Efficacy Profile of Echinacea ... - A.Vogel
Research Article Safety and Efficacy Profile of Echinacea ... - A.Vogel
Articles Efficacy of everolimus in advanced renal cell carcinoma: a ...
Articles Efficacy and safety of zotarolimus-eluting and sirolimus ...
Efficacy and safety of omalizumab in patients with ... - ResearchGate
Original Article Efficacy and safety of regional citrate anticoagulation ...
030801 Efficacy and Safety of Recombinant Human Activated
Safety and Efficacy of a Pentavalent Human– Bovine (WC3 ... - PATH
Original Articles Efficacy and safety of regional citrate ...
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
Comparative Efficacy and Safety of a Once-Daily Dosage ... - Nutraxin
Efficacy and safety of once-daily NVA237 in ... - BioMed Central
Articles Efficacy of nine-valent pneumococcal ... - The INCLEN Trust
Efficacy and Safety of the Novel Selective Nicotinic ... - GOLD
Efficacy and safety of single-dose omalizumab in antihistamine H1 ...
Articles Efficacy of boceprevir, an NS3 protease inhibitor, in ... - Natap